Key Developments: Becton Dickinson and Co (BDX.N)
103.11USD
1 Aug 2013
$-0.61 (-0.59%)
$103.72
$104.00
$104.00
$102.03
353,101
254,096
$104.98
$74.18
Latest Key Developments (Source: Significant Developments)
Becton Dickinson And Co Reaffirms FY 2013 Guidance
Becton Dickinson And Co reaffirmed its previously communicated guidance for fiscal 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to approach 5.0%, which is the upper end of the Company's previously communicated guidance range. Reported revenue growth is expected to be between 3.5% to 4.0%. Earnings per share from continuing operations for fiscal 2013 are expected to be between $5.65 and $5.68, or $5.72 and $5.75 after adjusting for a pending antitrust class action settlement. This represents growth of 6.5% to 7.0% over 2012 adjusted diluted earnings per share of $5.37, which excludes a pension settlement charge, in fiscal year 2012. On a currency-neutral basis, adjusted earnings per share growth is expected to be between 8.5 to 9.0%. After adjusting for the impact of the medical device excise tax and foreign currency, adjusted diluted earnings per share are expected to grow at the upper end of the Company's previously communicated guidance range of 11.0% to 11.5%. In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, up to $500 million of its common stock in fiscal year 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.99 billion and EPS of $5.74 for fiscal 2013. Full Article
Becton Dickinson And Co's BD Diagnostics and College Of American Pathologists Announce Strategic Alliance To Support Laboratory And Performance In India And China
BD Diagnostics, a segment of Becton Dickinson And Co, a global medical technology company, and the College of American Pathologists (CAP), announced the launch of a new strategic alliance that will provide solutions to advance laboratory for improved patient outcomes in China and India. BD and CAP announced the collaboration during the American Association for Clinical Chemistry (AACC) Annual Meeting in Houston, Texas. Full Article
Becton Dickinson And Co Declares Dividend
Becton Dickinson And Co announced that Board of Directors has declared a quarterly dividend of 49.5 cents per common share, payable on September 30, 2013 to holders of record on September 9, 2013. Full Article
Becton Dickinson And Co Appoints New CFO
Becton, Dickinson and Company announced that the appointment of Christopher Reidy as Chief Financial Officer and Executive Vice President of Administration, effective July 15, 2013. Mr. Reidy will report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President. Full Article
Becton Dickinson And Co Declares Dividend
Becton Dickinson And Co announced that it has declared a quarterly dividend of 49.5 cents per common share, payable on June 28, 2013 to holders of record on June 7, 2013. The indicated annual dividend rate is $1.98 per share. Full Article
Becton Dickinson And Co Raises FY 2013 Guidance
Becton Dickinson And Co announced that it has raised its previously communicated guidance for fiscal 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to be between 4.5% and 5.0%, or an increase of 50 basis points. Reported revenue growth guidance for fiscal 2013 remains consistent with the Company's previously guided range of 3.5% to 4.0%. Reported diluted earnings per share (EPS) from continuing operations are expected to be between $5.72 and $5.75, or an increase of $0.03 from the previous guidance range. On a currency-neutral basis, earnings per share are expected to increase 100 basis points to 8.5% to 9.0%. The Company reported revenues of $7.7 billion in the fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.996 billion, and EPS of $5.71 for fiscal 2013. Full Article
Becton Dickinson And Co's BD Rx Inc Announces FDA Approves Second Drug in BD Simplist Prefilled Injectable Line of Products
BD Rx Inc., a wholly-owned subsidiary of Becton Dickinson And Co announced that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic. BD Rx launched its first drug - BD Simplist Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine - on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error. The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation. The Company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses commonly relied on by clinicians in both the hospital and surgical center settings. Full Article
Becton Dickinson And Co Announces FDA 510(k) Clearance And Commercial Launch Of BD UltraSafe PLUS Passive Needle Guard
Becton Dickinson And Co announced commercial launch of a new passive needle guard technology, BD UltraSafe PLUS. The BD UltraSafe PLUS Passive Needle Guard has received 510(k) clearance as an anti-needlestick safety device. Full Article
Becton Dickinson And Co Raises Low End Of Prior FY 2013 Guidance To A Range In Line With Analysts' Estimates
Becton Dickinson And Co announced that the Company' positive first quarter results give the confidence to raise the bottom end of fiscal 2013 guidance range on revenues and earnings per share. The Company is raising the bottom end of its previously communicated revenue growth guidance for the year of 3.5% to 4.5% to 4.0% to 4.5% on a foreign currency-neutral basis. Reported revenue growth for fiscal 2013 is expected to be between 3.5% and 4.0%. Reported diluted earnings per share from continuing operations for fiscal 2013 is expected to be between $5.69 and $5.72. On a foreign currency-neutral basis, diluted earnings per share from continuing operations are expected to grow 7.5% to 8.0% over fiscal 2012 adjusted diluted earnings per share, or 10.5% to 11.0%, excluding the estimated impact of the medical device tax that went into effect last month under the U.S. healthcare reform law. The Company reported revenues of $7.7 billion in the fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $7.942 billion, and EPS of $5.65 for fiscal 2013. Full Article
Becton Dickinson And Co Declares Dividend
Becton Dickinson And Co announced that it has declared a quarterly dividend of 49.5 cents per common share, payable on March 29, 2013 to holders of record on March 8, 2013. Full Article
UPDATE 2-Becton Dickinson earnings helped by early flu season
* Adjusted operating fiscal Q1 EPS $1.53 vs Street view of $1.24

Earnings vs.
Estimates